431:
the binding of ATP and substrate to nRTKs, catalysis of phosphate transfer occurs in a cleft between these two lobes. It was found that nRTKs have some sequence preference around the target Tyr. For example, the Src preferred sequence is Glu–Glu/Asp–Ile–Tyr–Gly/Glu–Glu–Phe and Abl preferred sequence is Ile/Val–Tyr–Gly–Val–Leu/Val. Different preferred sequences around Tyr in Src and Abl suggest that these two types of nRTKs phosphorylates different targets. Non-receptor tyrosine kinases do not contain only a tyrosine kinase domain, nRTKs also possess domains that mediate protein-protein, protein-lipid, and protein-
570:(suppressor of cytokine signaling) proteins. These proteins contain a pseudo-substrate sequence thought to interfere with Jak substrate binding and phosphoryl transfer. In addition to a pseudo-substrate sequence, SOCS proteins possess an SH2 domain that binds to a phosphotyrosine in the Jak activation loop, which may facilitate interaction between the pseudosubstrate sequence and the kinase domain. Binding of the SH2 domain to the activation loop could also block substrate access directly or alter the conformation of the activation loop to repress catalytic activity.
563:, also lacking the pseudo-kinase domain, was able to mediate growth hormone signaling. The role of the pseudo-kinase domain in Jak regulation is still not fully understood. There are two tyrosine phosphorylation sites within the activation loop. It is known that the autophosphorylation of the first of these tyrosines is important for stimulation of tyrosine kinase activity and biological function, but the role of the second tyrosine is not clear.
4175:
25:
522:
second regulatory phosphorylation site in Src is Tyr-416. This is an autophosphorylation site in the activation loop. It was found that a phosphorylation of Tyr-416 and Tyr-416 can suppressing the transforming ability of the activating Tyr-527→Phe mutation by Tyr-416→Phe mutation leads to maximal stimulation of kinase activity.
443:) domains. The longer SH2 domain (~100 residues) binds phosphotyrosine (P-Tyr) residues in a sequence-specific manner. The P-Tyr interacts with SH domain in a deep cleft, which cannot bind unphosphorylated Tyr. The SH3 domain is smaller (~60 residues) and binds proline-containing sequences capable of forming a
492:
occurs via trans-autophosphorylation or phosphorylation by different nRTKs. It is possible to negatively regulate kinase activity by the phosphorylation of tyrosines outside of the activation loop. Protein tyrosine phosphatases (PTPs) restore nRTKs to their basal state of activity. In some cases PTPs
430:
sequences. One of the important domain of nRTKs is the tyrosine kinase catalytic domain, which is about 275 residues in length. The structure of the catalytic domain can be divided into a small and a large lobe, where ATP binds to the small lobe and the protein substrate binds to the large lobe. Upon
521:
and as a result of an carboxy-terminal truncation, v-Src lacks the negative regulatory site Tyr-527 leading this enzyme to be constitutively active that in turn causes uncontrolled growth of infected cells. Moreover, substitution of this tyrosine with phenylalanine in c-Src results in activation. A
554:
members possess a fully functional tyrosine kinase domain and additionally pseudo-kinase domain in which substitution of several key catalytic residues leads to inactivation of kinase activity. This pseudo-kinase domain is enzymatically nonfunctional, but maybe it plays a role in the regulation of
530:
contains SH3, SH2, and kinase domains in the same linear order as in Src, regulation of Abl is different. Abl lacks the negative regulatory phosphorylation site that is present in the carboxy terminus of Src, so the carboxy terminus of Abl does not have a functional role in the control of kinase
531:
activity. In a contrast to Src, mutations in the SH2 domain of Abl that abrogates phosphotyrosine binding do not activate Abl in vivo. For the repression of kinase activity of Abl is important the SH3 domain; mutations in the SH3 domain result in activation of Abl and cellular transformation.
1482:
Van Etten RA, Debnath J, Zhou H, Casasnovas JM (May 1995). "Introduction of a loss-of-function point mutation from the SH3 region of the
Caenorhabditis elegans sem-5 gene activates the transforming ability of c-abl in vivo and abolishes binding of proline-rich ligands in vitro".
578:
The mutation in a gene for non-receptor tyrosine kinase can results an aberrant activity of this enzyme. This pathologically increased activity of nRTK may be responsible for growth and progression of cancer cells, the induction of drug-resistance, formation of
547:
can be increased by phosphorylation of Tyr-493 in the activation loop by Src family member Lck. Conversely the phosphorylation of Tyr-492 inhibit the kinase activity of Zap70; the mutation of Tyr-492 to phenylalanine results in Zap70 hyperactivity.
543:(immunoreceptor tyrosine-based activation motif) sequences in the zeta chain of the T-cell receptor is thought to relieve an inhibitory restraint on the kinase domain, leading to stimulation of catalytic activity. Kinase activity of
475:
lipids that have been phosphorylated at particular positions on the head group. These enzymes can bind to activated signaling complexes at the membrane through PH domain interactions with phosphorylated phosphatidylinositol lipids.
972:
Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, Sparkes RS, Kubagawa H, Mohandas T, Quan S (January 1993). "Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia".
559:, in which the pseudo-kinase domain is deleted, showed that these mutant enzyme lacks catalytic activity in vitro and is not capable of interferon-mediated signal transduction. In contrast, another mutant of the Jak family
1059:
Songyang Z, Carraway KL, Eck MJ, Harrison SC, Feldman RA, Mohammadi M, Schlessinger J, Hubbard SR, Smith DP, Eng C (February 1995). "Catalytic specificity of protein-tyrosine kinases is critical for selective signalling".
1846:
525:
Both the SH2 and SH3 domains are important for a negative regulation of Src activity. Mutations in the SH2 and SH3 domains that disrupt binding of phosphotyrosine lead to activation of kinase activity. Although the nRTK
2873:
447:. Some nRTKs without SH2 and SH3 domains possess some subfamily-specific domains used for protein-protein interactions. For example, specific domains that target enzymes to the cytoplasmic part of cytokine receptors (
595:
are used for the targeted blockade of RTK, which block the extracellular domain of the receptor and prevent the binding of a ligand. For the specific blockade of nRTKs, however, low molecular weight substances called
296:, enzymes that can transfer the phosphate group from ATP to a tyrosine residue of a protein (phosphorylation). These enzymes regulate many cellular functions by switching on or switching off other enzymes in a cell.
1244:
Nada S, Okada M, MacAuley A, Cooper JA, Nakagawa H (May 1991). "Cloning of a complementary DNA for a protein-tyrosine kinase that specifically phosphorylates a negative regulatory site of p60c-src".
513:
tail. There are two important regulatory tyrosine phosphorylation sites. To repress kinase activity it is possible by phosphorylation of Tyr-527 in the carboxy-terminal tail of Src by the nRTK
1839:
303:(RTKs), the second subgroup of tyrosine kinases, the non-receptor tyrosine kinases are cytosolic enzymes. Thirty-two non-receptor tyrosine kinases have been identified in human cells (
1832:
394:
is involved in signaling mediated by B-cell receptor. Lyn is activated by stimulation of B-cell receptor, which leads to the recruitment and phosphorylation of Zap70-related nRTK,
43:
2747:
225:
1341:
Kmiecik TE, Shalloway D (April 1987). "Activation and suppression of pp60c-src transforming ability by mutation of its primary sites of tyrosine phosphorylation".
540:
3320:
1855:
244:
1782:"Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain"
517:. By the experiment of v-Src, an oncogenic variant of Src, the importance of this phosphorylation site was confirmed. This oncogenic v-Src is a product of the
459:-binding domain (Fak family). The nRTK Abl possess the SH2 and SH3 domains, but also possesses other domains for interactions: F actin–binding domain and a
3744:
2905:
509:
terminus, a region of positively charged residues, a short region with low sequence homology, SH3 and SH2 domains, a tyrosine kinase domain, and a short
1898:
2343:
1386:"Mutational analysis of the Src SH3 domain: the same residues of the ligand binding surface are important for intra- and intermolecular interactions"
467:
and is found in both the nucleus and the cytoplasm. In addition to SH2 and SH3 domains, Btk/Tec subfamily of nRTKs possess another modular domain, a
3617:
2850:
2486:
2394:
2291:
662:
2005:
1961:
3043:
2808:
1512:"Syk is activated by phosphotyrosine-containing peptides representing the tyrosine-based activation motifs of the high affinity receptor for IgE"
591:
blocks intracellular processes involved in the tumor transformation of cells and / or maintenance of malignant phenotype of tumor cells. Usually
587:. The inhibition of nRTKs could help to a treatment of these tumors. Some of nRTKs inhibitors are already tested as an anti-cancer agents. This
3358:
1888:
3000:
3028:
2787:
2710:
1602:"Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase"
4200:
3396:
3387:
3087:
3082:
3077:
3072:
484:
The most common theme in nRTKs and RTK regulation is tyrosine phosphorylation. With few exceptions, phosphorylation of tyrosines in the
3281:
3272:
2830:
3894:
3063:
2239:
61:
1148:"Identification and analysis of PH domain-containing targets of phosphatidylinositol 3-kinase using a novel in vivo assay in yeast"
913:
Vihinen M, Vetrie D, Maniar HS, Ochs HD, Zhu Q, VorechovskĂ˝ I, Webster AD, Notarangelo LD, Nilsson L, Sowadski JM (December 1994).
2966:
2369:
1295:
Cooper JA, Gould KL, Cartwright CA, Hunter T (March 1986). "Tyr527 is phosphorylated in pp60c-src: implications for regulation".
237:
2742:
1651:"Distinct domains of the protein tyrosine kinase tyk2 required for binding of interferon-alpha/beta and for signal transduction"
386:, binds to this T-cell receptor and then participates in downstream signaling events that mediate transcriptional activation of
2898:
2798:
2000:
1976:
1956:
422:-spanning region. Most of the nRTKs are localized in the cytoplasm, but some nRTKs are anchored to the cell membrane through
188:
164:
4050:
2605:
1553:"Distinct tyrosine phosphorylation sites in ZAP-70 mediate activation and negative regulation of antigen receptor function"
600:(TKIs) are used, that block the transduction cascade either at the intracytosplasmatic level, or directly block the nRTKs.
3111:
2557:
2010:
539:
The kinase activity of Syk is regulated by the SH2 domains. Binding of the two SH2 domains to the tyrosine-phosphorylated
4165:
1739:
Starr R, Novak U, Willson TA, Inglese M, Murphy V, Alexander WS, Metcalf D, Nicola NA, Hilton DJ, Ernst M (August 1997).
3474:
3465:
2763:
2738:
2729:
2244:
1741:"Distinct roles for leukemia inhibitory factor receptor alpha-chain and gp130 in cell type-specific signal transduction"
3848:
3839:
3775:
3603:
1871:
782:
464:
403:
3819:
2622:
838:
399:
1146:
Isakoff SJ, Cardozo T, Andreev J, Li Z, Ferguson KM, Abagyan R, Lemmon MA, Aronheim A, Skolnik EY (September 1998).
3286:
468:
4035:
4151:
4138:
4125:
4112:
4099:
4086:
4073:
2891:
597:
300:
4045:
182:
3999:
3942:
2936:
2922:
2845:
2432:
1935:
1917:
1780:
Sasaki A, Yasukawa H, Suzuki A, Kamizono S, Syoda T, Kinjyo I, Sasaki M, Johnston JA, Yoshimura A (June 1999).
426:
modification. These enzymes commonly have a modular construction and individual domains are joined together by
402:, is also involved in signaling mediated by the B-cell receptor. Mutations in the Btk gene are responsible for
310:). Non-receptor tyrosine kinases regulate cell growth, proliferation, differentiation, adhesion, migration and
304:
87:
169:
3947:
3660:
3651:
2638:
2348:
2318:
2303:
2266:
693:
687:
351:
281:
2949:
1926:
285:
249:
3968:
3887:
3612:
3296:
2719:
2530:
2298:
657:
651:
592:
514:
157:
4040:
1692:"Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop"
2122:
1304:
1253:
1069:
926:
472:
338:
in the immune system. Signaling by many receptors is dependent on nRTKs including T-cell receptors (
4004:
3310:
2701:
2574:
327:
185:
109:
4195:
3937:
3694:
3684:
3675:
3503:
3494:
2107:
2072:
1811:
1435:"Mutagenic analysis of the roles of SH2 and SH3 domains in regulation of the Abl tyrosine kinase"
1366:
1277:
1226:
1093:
1041:
998:
895:
721:
711:
705:
584:
518:
460:
355:
2883:
1824:
378:. When antigen binds to T-cell receptor, Lck becomes autophosphorylated and phosphorylates the
3728:
1995:
1951:
1803:
1762:
1721:
1672:
1631:
1582:
1533:
1492:
1464:
1415:
1358:
1320:
1269:
1218:
1177:
1128:
1085:
1033:
1016:
Neet K, Hunter T (February 1996). "Vertebrate non-receptor protein-tyrosine kinase families".
990:
954:
887:
756:
749:
556:
444:
435:
interactions. One of the protein-protein interaction domains in nRTKs are the Src homology 2 (
176:
414:
Unlike receptor tyrosine kinases, nRTKs lack receptor-like features such as an extracellular
3983:
3978:
3952:
3880:
3005:
2991:
1966:
1944:
1940:
1793:
1752:
1711:
1703:
1662:
1621:
1613:
1572:
1564:
1523:
1454:
1446:
1405:
1397:
1350:
1312:
1261:
1208:
1167:
1159:
1120:
1111:
Kuriyan J, Cowburn D (1997). "Modular peptide recognition domains in eukaryotic signaling".
1077:
1025:
982:
944:
934:
879:
588:
510:
3252:
2663:
2204:
870:
Weiss A, Littman DR (January 1994). "Signal transduction by lymphocyte antigen receptors".
145:
4030:
4014:
3927:
3593:
3262:
3247:
3237:
3232:
3212:
3207:
3202:
3197:
3192:
3183:
2918:
2686:
2681:
2442:
2437:
2413:
2408:
2374:
2271:
2199:
2023:
644:
489:
485:
427:
343:
339:
293:
121:
1308:
1257:
1073:
930:
915:"Structural basis for chromosome X-linked agammaglobulinemia: a tyrosine kinase disease"
92:
4179:
4068:
4009:
3723:
3718:
3713:
3097:
2914:
2385:
1551:
Kong G, Dalton M, Bubeck
Wardenburg J, Straus D, Kurosaki T, Chan AC (September 1996).
1401:
1172:
1147:
1029:
744:
739:
734:
506:
456:
220:
1716:
1691:
1649:
Velazquez L, Mogensen KE, Barbieri G, Fellous M, Uzé G, Pellegrini S (February 1995).
1626:
1601:
1577:
1552:
1459:
1434:
1410:
1385:
1213:
1196:
200:
4189:
3973:
3932:
3159:
3020:
2464:
2403:
2276:
1798:
1781:
1354:
1124:
986:
949:
914:
883:
419:
347:
315:
195:
1815:
1370:
1045:
1002:
899:
3922:
3704:
3415:
3406:
3150:
2420:
2258:
1281:
1230:
1097:
728:
551:
448:
367:
4146:
4081:
3917:
2323:
1893:
204:
4174:
1600:
Wilks AF, Harpur AG, Kurban RR, Ralph SJ, ZĂĽrcher G, Ziemiecki A (April 1991).
1163:
3829:
3824:
3814:
3809:
3800:
3749:
3665:
3555:
2513:
2308:
1985:
848:
843:
833:
828:
822:
767:
762:
698:
580:
527:
502:
440:
436:
423:
371:
2835:
1757:
1740:
1528:
1511:
939:
4120:
4094:
2777:
1990:
1908:
1316:
311:
277:
270:
1807:
1667:
1650:
1766:
1725:
1707:
1690:
Feng J, Witthuhn BA, Matsuda T, Kohlhuber F, Kerr IM, Ihle JN (May 1997).
1676:
1635:
1617:
1586:
1568:
1537:
1496:
1468:
1450:
1419:
1362:
1324:
1273:
1222:
1181:
1132:
1089:
1037:
994:
958:
891:
3564:
2971:
618:
612:
452:
387:
307:
133:
2855:
2579:
2425:
289:
152:
4133:
3903:
3853:
3116:
3052:
3047:
2860:
2648:
2643:
2353:
1265:
1081:
815:
555:
Jak activity. The experiments with a mutant of the Jak family member
488:
of nRTKs leads to an increase in enzymatic activity. Activation loop
415:
335:
331:
273:
232:
128:
116:
104:
1197:"From form to function: signaling by protein tyrosine phosphatases"
4107:
3641:
3519:
3484:
3479:
3455:
3257:
3242:
3227:
3222:
3217:
3169:
3164:
3140:
3135:
3126:
3038:
3033:
3010:
2981:
2976:
2658:
2653:
2615:
2600:
2567:
2562:
2523:
2518:
2506:
2501:
2496:
2491:
2479:
2457:
2452:
2447:
2224:
2219:
2214:
2209:
2169:
2164:
2102:
2097:
2092:
2087:
2062:
2057:
2052:
2047:
2042:
2037:
2032:
680:
544:
383:
379:
292:. Non-receptor tyrosine kinases are a subgroup of protein family
3759:
3689:
3636:
3627:
3588:
3579:
3569:
3450:
3441:
3431:
3377:
3368:
3353:
3344:
3334:
3329:
3305:
3106:
2958:
2840:
2825:
2610:
2550:
2545:
2540:
2535:
2474:
2469:
2313:
2286:
2281:
2194:
2189:
2184:
2179:
2174:
2151:
2146:
2141:
2136:
2131:
2082:
2077:
2067:
777:
716:
675:
669:
639:
633:
623:
567:
560:
140:
3876:
3540:
2934:
2887:
1828:
3790:
3785:
3780:
3754:
810:
804:
797:
792:
787:
772:
432:
395:
391:
375:
363:
359:
18:
2874:
deficiencies of intracellular signaling peptides and proteins
314:, and they are critical components in the regulation of the
3872:
406:, a disease characterized by the lack of mature B-cells.
1384:
Erpel T, Superti-Furga G, Courtneidge SA (March 1995).
39:
4163:
276:
that is responsible for catalysing the transfer of a
4059:
4023:
3992:
3961:
3910:
3838:
3799:
3768:
3737:
3703:
3674:
3650:
3626:
3602:
3578:
3554:
3512:
3493:
3464:
3440:
3424:
3405:
3386:
3367:
3343:
3319:
3295:
3271:
3182:
3149:
3125:
3096:
3062:
3019:
2990:
2957:
2948:
2818:
2797:
2776:
2756:
2728:
2709:
2699:
2674:
2631:
2590:
2393:
2383:
2362:
2336:
2257:
1975:
1925:
1916:
1907:
1881:
1862:
608:Examples of non-receptor tyrosine kinases include:
326:The main function of nRTKs is their involvement in
243:
231:
219:
214:
194:
175:
163:
151:
139:
127:
115:
103:
98:
86:
81:
76:
34:
may be too technical for most readers to understand
2748:Sh2 domain-containing protein tyrosine phosphatase
1336:
1334:
3888:
2899:
1856:Intracellular signaling peptides and proteins
1840:
8:
3895:
3881:
3873:
3551:
3537:
2954:
2945:
2931:
2906:
2892:
2884:
2743:Receptor-like protein tyrosine phosphatase
2706:
2390:
1922:
1913:
1847:
1833:
1825:
1510:Shiue L, Zoller MJ, Brugge JS (May 1995).
211:
2344:Cyclin-dependent kinase inhibitor protein
1797:
1756:
1715:
1666:
1625:
1576:
1527:
1458:
1409:
1212:
1171:
948:
938:
62:Learn how and when to remove this message
46:, without removing the technical details.
2851:Phosphatidylethanolamine binding protein
2487:Interleukin-1 receptor associated kinase
1899:Ca2+/calmodulin-dependent protein kinase
4170:
862:
2606:Focal adhesion protein-tyrosine kinase
1889:Intracellular calcium-sensing proteins
73:
44:make it understandable to non-experts
7:
505:contain the same typical structure:
493:positively regulate nRTKs activity.
1195:Tonks NK, Neel BG (November 1996).
2831:Signal transducing adaptor protein
2006:3',5'-cyclic-GMP phosphodiesterase
1962:3',5'-cyclic-AMP phosphodiesterase
1433:Mayer BJ, Baltimore D (May 1994).
1402:10.1002/j.1460-2075.1995.tb07077.x
1030:10.1046/j.1365-2443.1996.d01-234.x
14:
2826:Activating transcription factor 6
2240:G protein-coupled receptor kinase
390:genes. Another Src family member
380:zeta chain of the T-cell receptor
350:), Ig receptors, erythropoietin (
4173:
2370:Phosphoinositide phospholipase C
1799:10.1046/j.1365-2443.1999.00263.x
1125:10.1146/annurev.biophys.26.1.259
370:require for their signaling the
23:
469:pleckstrin homology (PH) domain
2809:GTP-binding protein regulators
2799:GTP-binding protein regulators
1113:Annu Rev Biophys Biomol Struct
1:
3543:Non-receptor tyrosine kinases
2558:Rho-associated protein kinase
1214:10.1016/S0092-8674(00)81357-4
382:, subsequently another nRTK,
2764:Dual-specificity phosphatase
2739:protein tyrosine phosphatase
2245:AMP-activated protein kinase
1355:10.1016/0092-8674(87)90756-2
987:10.1016/0092-8674(93)90667-F
919:Proc. Natl. Acad. Sci. U.S.A
884:10.1016/0092-8674(94)90334-4
263:non-receptor tyrosine kinase
77:Non-receptor tyrosine kinase
2788:apoptosis signaling pathway
566:JAKs are also regulated by
471:. These PH domains bind to
465:nuclear localization signal
404:X-linked agammaglobulinemia
4217:
4201:Enzymes of known structure
288:, to tyrosine residues in
4051:Michaelis–Menten kinetics
3550:
3536:
2944:
2937:Receptor tyrosine kinases
2930:
2869:
2632:Serine/threonine/tyrosine
2235:
2118:
2019:
598:Tyrosine-kinase inhibitor
445:polyproline type II helix
301:receptor tyrosine kinases
210:
3943:Diffusion-limited enzyme
2846:Olfactory marker protein
2433:Glycogen synthase kinase
1936:Heterotrimeric G protein
1758:10.1074/jbc.272.32.19982
1529:10.1074/jbc.270.18.10498
1164:10.1093/emboj/17.18.5374
940:10.1073/pnas.91.26.12803
2950:Growth factor receptors
2639:Dual-specificity kinase
2349:Cyclin-dependent kinase
1317:10.1126/science.2420005
282:nucleoside triphosphate
16:Class of kinase enzymes
1668:10.1074/jbc.270.7.3327
455:-binding domain and a
418:-binding domain and a
4036:Eadie–Hofstee diagram
3969:Allosteric regulation
2720:Protein phosphatase 2
2531:p21-activated kinases
1708:10.1128/mcb.17.5.2497
1618:10.1128/MCB.11.4.2057
1569:10.1128/MCB.16.9.5026
1451:10.1128/mcb.14.5.2883
593:monoclonal antibodies
451:) or two domains: an
342:), B-cell receptors (
4046:Lineweaver–Burk plot
3021:PDGF receptor family
2123:G beta-gamma complex
501:Tyrosine kinases of
473:phosphatidylinositol
3425:ROS receptor family
2959:EGF receptor family
2702:protein phosphatase
2575:Ribosomal s6 kinase
1309:1986Sci...231.1431C
1258:1991Natur.351...69N
1074:1995Natur.373..536S
931:1994PNAS...9112803V
356:prolactin receptors
346:), IL-2 receptors (
328:signal transduction
4005:Enzyme superfamily
3938:Enzyme promiscuity
1872:MAP kinase pathway
585:neovascularization
535:ZAP70/Syk and JAKs
519:Rous sarcoma virus
461:DNA-binding domain
4161:
4160:
3870:
3869:
3866:
3865:
3862:
3861:
3532:
3531:
3528:
3527:
3178:
3177:
2881:
2880:
2836:I-kappa B protein
2772:
2771:
2695:
2694:
2332:
2331:
2253:
2252:
1996:Guanylate cyclase
1952:Adenylate cyclase
1522:(18): 10498–502.
259:
258:
255:
254:
158:metabolic pathway
72:
71:
64:
4208:
4178:
4177:
4169:
4041:Hanes–Woolf plot
3984:Enzyme activator
3979:Enzyme inhibitor
3953:Enzyme catalysis
3897:
3890:
3883:
3874:
3552:
3538:
2992:Insulin receptor
2955:
2946:
2932:
2919:tyrosine kinases
2908:
2901:
2894:
2885:
2711:Serine/threonine
2707:
2395:Serine/threonine
2391:
2011:Protein kinase G
1967:Protein kinase A
1923:
1914:
1849:
1842:
1835:
1826:
1820:
1819:
1801:
1777:
1771:
1770:
1760:
1736:
1730:
1729:
1719:
1687:
1681:
1680:
1670:
1646:
1640:
1639:
1629:
1597:
1591:
1590:
1580:
1548:
1542:
1541:
1531:
1507:
1501:
1500:
1479:
1473:
1472:
1462:
1430:
1424:
1423:
1413:
1381:
1375:
1374:
1338:
1329:
1328:
1303:(4744): 1431–4.
1292:
1286:
1285:
1266:10.1038/351069a0
1241:
1235:
1234:
1216:
1192:
1186:
1185:
1175:
1143:
1137:
1136:
1108:
1102:
1101:
1082:10.1038/373536a0
1056:
1050:
1049:
1013:
1007:
1006:
969:
963:
962:
952:
942:
910:
904:
903:
867:
589:targeted therapy
511:carboxy-terminal
398:. Another nRTK,
294:tyrosine kinases
212:
74:
67:
60:
56:
53:
47:
27:
26:
19:
4216:
4215:
4211:
4210:
4209:
4207:
4206:
4205:
4186:
4185:
4184:
4172:
4164:
4162:
4157:
4069:Oxidoreductases
4055:
4031:Enzyme kinetics
4019:
4015:List of enzymes
3988:
3957:
3928:Catalytic triad
3906:
3901:
3871:
3858:
3834:
3795:
3764:
3733:
3699:
3670:
3646:
3622:
3598:
3574:
3546:
3524:
3508:
3489:
3460:
3436:
3420:
3401:
3382:
3363:
3339:
3315:
3291:
3267:
3174:
3145:
3121:
3092:
3058:
3015:
2986:
2940:
2926:
2915:Protein kinases
2912:
2882:
2877:
2865:
2814:
2793:
2768:
2752:
2724:
2691:
2682:Arginine kinase
2670:
2627:
2586:
2379:
2375:Phospholipase C
2358:
2328:
2249:
2231:
2161:
2128:
2114:
2029:
2024:G alpha subunit
2015:
1971:
1903:
1877:
1858:
1853:
1823:
1779:
1778:
1774:
1751:(32): 19982–6.
1738:
1737:
1733:
1702:(5): 2497–501.
1696:Mol. Cell. Biol
1689:
1688:
1684:
1648:
1647:
1643:
1606:Mol. Cell. Biol
1599:
1598:
1594:
1557:Mol. Cell. Biol
1550:
1549:
1545:
1509:
1508:
1504:
1491:(10): 1977–88.
1481:
1480:
1476:
1439:Mol. Cell. Biol
1432:
1431:
1427:
1383:
1382:
1378:
1340:
1339:
1332:
1294:
1293:
1289:
1252:(6321): 69–72.
1243:
1242:
1238:
1194:
1193:
1189:
1158:(18): 5374–87.
1145:
1144:
1140:
1110:
1109:
1105:
1068:(6514): 536–9.
1058:
1057:
1053:
1015:
1014:
1010:
971:
970:
966:
925:(26): 12803–7.
912:
911:
907:
869:
868:
864:
860:
855:
606:
576:
537:
499:
490:phosphorylation
486:activation loop
482:
428:flexible linker
412:
324:
284:donor, such as
68:
57:
51:
48:
40:help improve it
37:
28:
24:
17:
12:
11:
5:
4214:
4212:
4204:
4203:
4198:
4188:
4187:
4183:
4182:
4159:
4158:
4156:
4155:
4142:
4129:
4116:
4103:
4090:
4077:
4063:
4061:
4057:
4056:
4054:
4053:
4048:
4043:
4038:
4033:
4027:
4025:
4021:
4020:
4018:
4017:
4012:
4007:
4002:
3996:
3994:
3993:Classification
3990:
3989:
3987:
3986:
3981:
3976:
3971:
3965:
3963:
3959:
3958:
3956:
3955:
3950:
3945:
3940:
3935:
3930:
3925:
3920:
3914:
3912:
3908:
3907:
3902:
3900:
3899:
3892:
3885:
3877:
3868:
3867:
3864:
3863:
3860:
3859:
3857:
3856:
3851:
3845:
3843:
3836:
3835:
3833:
3832:
3827:
3822:
3817:
3812:
3806:
3804:
3797:
3796:
3794:
3793:
3788:
3783:
3778:
3772:
3770:
3766:
3765:
3763:
3762:
3757:
3752:
3747:
3741:
3739:
3735:
3734:
3732:
3731:
3726:
3721:
3716:
3710:
3708:
3701:
3700:
3698:
3697:
3692:
3687:
3681:
3679:
3672:
3671:
3669:
3668:
3663:
3657:
3655:
3648:
3647:
3645:
3644:
3639:
3633:
3631:
3624:
3623:
3621:
3620:
3615:
3609:
3607:
3600:
3599:
3597:
3596:
3591:
3585:
3583:
3576:
3575:
3573:
3572:
3567:
3561:
3559:
3548:
3547:
3541:
3534:
3533:
3530:
3529:
3526:
3525:
3523:
3522:
3516:
3514:
3510:
3509:
3507:
3506:
3500:
3498:
3491:
3490:
3488:
3487:
3482:
3477:
3471:
3469:
3462:
3461:
3459:
3458:
3453:
3447:
3445:
3442:AATYK receptor
3438:
3437:
3435:
3434:
3428:
3426:
3422:
3421:
3419:
3418:
3412:
3410:
3403:
3402:
3400:
3399:
3393:
3391:
3384:
3383:
3381:
3380:
3374:
3372:
3365:
3364:
3362:
3361:
3356:
3350:
3348:
3341:
3340:
3338:
3337:
3332:
3326:
3324:
3317:
3316:
3314:
3313:
3308:
3302:
3300:
3293:
3292:
3290:
3289:
3284:
3278:
3276:
3269:
3268:
3266:
3265:
3260:
3255:
3250:
3245:
3240:
3235:
3230:
3225:
3220:
3215:
3210:
3205:
3200:
3195:
3189:
3187:
3180:
3179:
3176:
3175:
3173:
3172:
3167:
3162:
3156:
3154:
3147:
3146:
3144:
3143:
3138:
3132:
3130:
3123:
3122:
3120:
3119:
3114:
3109:
3103:
3101:
3098:VEGF receptors
3094:
3093:
3091:
3090:
3085:
3080:
3075:
3069:
3067:
3060:
3059:
3057:
3056:
3050:
3041:
3036:
3031:
3025:
3023:
3017:
3016:
3014:
3013:
3008:
3003:
2997:
2995:
2988:
2987:
2985:
2984:
2979:
2974:
2969:
2963:
2961:
2952:
2942:
2941:
2935:
2928:
2927:
2913:
2911:
2910:
2903:
2896:
2888:
2879:
2878:
2870:
2867:
2866:
2864:
2863:
2858:
2853:
2848:
2843:
2838:
2833:
2828:
2822:
2820:
2816:
2815:
2813:
2812:
2803:
2801:
2795:
2794:
2792:
2791:
2782:
2780:
2774:
2773:
2770:
2769:
2767:
2766:
2760:
2758:
2754:
2753:
2751:
2750:
2745:
2735:
2733:
2726:
2725:
2723:
2722:
2716:
2714:
2704:
2697:
2696:
2693:
2692:
2690:
2689:
2684:
2678:
2676:
2672:
2671:
2669:
2668:
2667:
2666:
2661:
2656:
2651:
2646:
2635:
2633:
2629:
2628:
2626:
2625:
2620:
2619:
2618:
2613:
2603:
2597:
2595:
2588:
2587:
2585:
2584:
2583:
2582:
2572:
2571:
2570:
2565:
2555:
2554:
2553:
2548:
2543:
2538:
2528:
2527:
2526:
2521:
2511:
2510:
2509:
2504:
2499:
2494:
2484:
2483:
2482:
2477:
2472:
2462:
2461:
2460:
2455:
2450:
2445:
2440:
2430:
2429:
2428:
2418:
2417:
2416:
2411:
2400:
2398:
2388:
2386:protein kinase
2381:
2380:
2378:
2377:
2372:
2366:
2364:
2360:
2359:
2357:
2356:
2351:
2346:
2340:
2338:
2334:
2333:
2330:
2329:
2327:
2326:
2321:
2316:
2311:
2306:
2301:
2296:
2295:
2294:
2289:
2284:
2274:
2269:
2263:
2261:
2255:
2254:
2251:
2250:
2248:
2247:
2242:
2236:
2233:
2232:
2230:
2229:
2228:
2227:
2222:
2217:
2212:
2207:
2202:
2197:
2192:
2187:
2182:
2177:
2172:
2167:
2159:
2156:
2155:
2154:
2149:
2144:
2139:
2134:
2126:
2119:
2116:
2115:
2113:
2112:
2111:
2110:
2105:
2100:
2095:
2090:
2085:
2080:
2075:
2070:
2065:
2060:
2055:
2050:
2045:
2040:
2035:
2027:
2020:
2017:
2016:
2014:
2013:
2008:
2003:
1998:
1993:
1988:
1982:
1980:
1973:
1972:
1970:
1969:
1964:
1959:
1954:
1949:
1948:
1947:
1932:
1930:
1920:
1918:Heterotrimeric
1911:
1905:
1904:
1902:
1901:
1896:
1891:
1885:
1883:
1879:
1878:
1876:
1875:
1866:
1864:
1860:
1859:
1854:
1852:
1851:
1844:
1837:
1829:
1822:
1821:
1772:
1731:
1682:
1661:(7): 3327–34.
1641:
1612:(4): 2057–65.
1592:
1563:(9): 5026–35.
1543:
1502:
1474:
1445:(5): 2883–94.
1425:
1376:
1330:
1287:
1236:
1187:
1138:
1103:
1051:
1008:
964:
905:
861:
859:
856:
854:
853:
852:
851:
846:
841:
836:
831:
820:
819:
818:
813:
802:
801:
800:
795:
790:
785:
780:
775:
770:
765:
754:
753:
752:
747:
742:
737:
726:
725:
724:
719:
714:
703:
702:
701:
696:
685:
684:
683:
678:
667:
666:
665:
660:
649:
648:
647:
642:
630:
629:
628:
627:
626:
621:
605:
602:
575:
572:
536:
533:
498:
495:
481:
478:
457:focal adhesion
424:amino-terminal
411:
408:
374:family member
323:
320:
257:
256:
253:
252:
247:
241:
240:
235:
229:
228:
223:
217:
216:
208:
207:
198:
192:
191:
180:
173:
172:
167:
161:
160:
155:
149:
148:
143:
137:
136:
131:
125:
124:
119:
113:
112:
107:
101:
100:
96:
95:
90:
84:
83:
79:
78:
70:
69:
31:
29:
22:
15:
13:
10:
9:
6:
4:
3:
2:
4213:
4202:
4199:
4197:
4194:
4193:
4191:
4181:
4176:
4171:
4167:
4153:
4149:
4148:
4143:
4140:
4136:
4135:
4130:
4127:
4123:
4122:
4117:
4114:
4110:
4109:
4104:
4101:
4097:
4096:
4091:
4088:
4084:
4083:
4078:
4075:
4071:
4070:
4065:
4064:
4062:
4058:
4052:
4049:
4047:
4044:
4042:
4039:
4037:
4034:
4032:
4029:
4028:
4026:
4022:
4016:
4013:
4011:
4010:Enzyme family
4008:
4006:
4003:
4001:
3998:
3997:
3995:
3991:
3985:
3982:
3980:
3977:
3975:
3974:Cooperativity
3972:
3970:
3967:
3966:
3964:
3960:
3954:
3951:
3949:
3946:
3944:
3941:
3939:
3936:
3934:
3933:Oxyanion hole
3931:
3929:
3926:
3924:
3921:
3919:
3916:
3915:
3913:
3909:
3905:
3898:
3893:
3891:
3886:
3884:
3879:
3878:
3875:
3855:
3852:
3850:
3847:
3846:
3844:
3841:
3837:
3831:
3828:
3826:
3823:
3821:
3818:
3816:
3813:
3811:
3808:
3807:
3805:
3802:
3798:
3792:
3789:
3787:
3784:
3782:
3779:
3777:
3774:
3773:
3771:
3767:
3761:
3758:
3756:
3753:
3751:
3748:
3746:
3743:
3742:
3740:
3736:
3730:
3727:
3725:
3722:
3720:
3717:
3715:
3712:
3711:
3709:
3706:
3702:
3696:
3693:
3691:
3688:
3686:
3683:
3682:
3680:
3677:
3673:
3667:
3664:
3662:
3659:
3658:
3656:
3653:
3649:
3643:
3640:
3638:
3635:
3634:
3632:
3629:
3625:
3619:
3616:
3614:
3611:
3610:
3608:
3605:
3601:
3595:
3592:
3590:
3587:
3586:
3584:
3581:
3577:
3571:
3568:
3566:
3563:
3562:
3560:
3557:
3553:
3549:
3545:(EC 2.7.10.2)
3544:
3539:
3535:
3521:
3518:
3517:
3515:
3513:uncategorised
3511:
3505:
3502:
3501:
3499:
3496:
3492:
3486:
3483:
3481:
3478:
3476:
3473:
3472:
3470:
3467:
3463:
3457:
3454:
3452:
3449:
3448:
3446:
3443:
3439:
3433:
3430:
3429:
3427:
3423:
3417:
3414:
3413:
3411:
3408:
3407:MuSK receptor
3404:
3398:
3395:
3394:
3392:
3389:
3385:
3379:
3376:
3375:
3373:
3370:
3369:PTK7 receptor
3366:
3360:
3357:
3355:
3352:
3351:
3349:
3346:
3342:
3336:
3333:
3331:
3328:
3327:
3325:
3322:
3318:
3312:
3309:
3307:
3304:
3303:
3301:
3298:
3294:
3288:
3285:
3283:
3280:
3279:
3277:
3274:
3270:
3264:
3261:
3259:
3256:
3254:
3251:
3249:
3246:
3244:
3241:
3239:
3236:
3234:
3231:
3229:
3226:
3224:
3221:
3219:
3216:
3214:
3211:
3209:
3206:
3204:
3201:
3199:
3196:
3194:
3191:
3190:
3188:
3185:
3181:
3171:
3168:
3166:
3163:
3161:
3158:
3157:
3155:
3152:
3148:
3142:
3139:
3137:
3134:
3133:
3131:
3128:
3124:
3118:
3115:
3113:
3110:
3108:
3105:
3104:
3102:
3099:
3095:
3089:
3086:
3084:
3081:
3079:
3076:
3074:
3071:
3070:
3068:
3065:
3061:
3054:
3051:
3049:
3045:
3042:
3040:
3037:
3035:
3032:
3030:
3027:
3026:
3024:
3022:
3018:
3012:
3009:
3007:
3004:
3002:
2999:
2998:
2996:
2993:
2989:
2983:
2980:
2978:
2975:
2973:
2970:
2968:
2965:
2964:
2962:
2960:
2956:
2953:
2951:
2947:
2943:
2939:(EC 2.7.10.1)
2938:
2933:
2929:
2924:
2920:
2916:
2909:
2904:
2902:
2897:
2895:
2890:
2889:
2886:
2876:
2875:
2868:
2862:
2859:
2857:
2854:
2852:
2849:
2847:
2844:
2842:
2839:
2837:
2834:
2832:
2829:
2827:
2824:
2823:
2821:
2817:
2811:
2810:
2805:
2804:
2802:
2800:
2796:
2790:
2789:
2784:
2783:
2781:
2779:
2775:
2765:
2762:
2761:
2759:
2755:
2749:
2746:
2744:
2740:
2737:
2736:
2734:
2731:
2727:
2721:
2718:
2717:
2715:
2712:
2708:
2705:
2703:
2698:
2688:
2685:
2683:
2680:
2679:
2677:
2673:
2665:
2662:
2660:
2657:
2655:
2652:
2650:
2647:
2645:
2642:
2641:
2640:
2637:
2636:
2634:
2630:
2624:
2621:
2617:
2614:
2612:
2609:
2608:
2607:
2604:
2602:
2599:
2598:
2596:
2593:
2589:
2581:
2578:
2577:
2576:
2573:
2569:
2566:
2564:
2561:
2560:
2559:
2556:
2552:
2549:
2547:
2544:
2542:
2539:
2537:
2534:
2533:
2532:
2529:
2525:
2522:
2520:
2517:
2516:
2515:
2512:
2508:
2505:
2503:
2500:
2498:
2495:
2493:
2490:
2489:
2488:
2485:
2481:
2478:
2476:
2473:
2471:
2468:
2467:
2466:
2463:
2459:
2456:
2454:
2451:
2449:
2446:
2444:
2441:
2439:
2436:
2435:
2434:
2431:
2427:
2424:
2423:
2422:
2419:
2415:
2412:
2410:
2407:
2406:
2405:
2404:Casein kinase
2402:
2401:
2399:
2396:
2392:
2389:
2387:
2382:
2376:
2373:
2371:
2368:
2367:
2365:
2361:
2355:
2352:
2350:
2347:
2345:
2342:
2341:
2339:
2335:
2325:
2322:
2320:
2317:
2315:
2312:
2310:
2307:
2305:
2302:
2300:
2297:
2293:
2290:
2288:
2285:
2283:
2280:
2279:
2278:
2275:
2273:
2270:
2268:
2265:
2264:
2262:
2260:
2256:
2246:
2243:
2241:
2238:
2237:
2234:
2226:
2223:
2221:
2218:
2216:
2213:
2211:
2208:
2206:
2203:
2201:
2198:
2196:
2193:
2191:
2188:
2186:
2183:
2181:
2178:
2176:
2173:
2171:
2168:
2166:
2163:
2162:
2157:
2153:
2150:
2148:
2145:
2143:
2140:
2138:
2135:
2133:
2130:
2129:
2124:
2121:
2120:
2117:
2109:
2106:
2104:
2101:
2099:
2096:
2094:
2091:
2089:
2086:
2084:
2081:
2079:
2076:
2074:
2071:
2069:
2066:
2064:
2061:
2059:
2056:
2054:
2051:
2049:
2046:
2044:
2041:
2039:
2036:
2034:
2031:
2030:
2025:
2022:
2021:
2018:
2012:
2009:
2007:
2004:
2002:
1999:
1997:
1994:
1992:
1989:
1987:
1984:
1983:
1981:
1978:
1974:
1968:
1965:
1963:
1960:
1958:
1955:
1953:
1950:
1946:
1942:
1939:
1938:
1937:
1934:
1933:
1931:
1928:
1924:
1921:
1919:
1915:
1912:
1910:
1906:
1900:
1897:
1895:
1892:
1890:
1887:
1886:
1884:
1880:
1874:
1873:
1868:
1867:
1865:
1861:
1857:
1850:
1845:
1843:
1838:
1836:
1831:
1830:
1827:
1817:
1813:
1809:
1805:
1800:
1795:
1792:(6): 339–51.
1791:
1787:
1783:
1776:
1773:
1768:
1764:
1759:
1754:
1750:
1746:
1745:J. Biol. Chem
1742:
1735:
1732:
1727:
1723:
1718:
1713:
1709:
1705:
1701:
1697:
1693:
1686:
1683:
1678:
1674:
1669:
1664:
1660:
1656:
1655:J. Biol. Chem
1652:
1645:
1642:
1637:
1633:
1628:
1623:
1619:
1615:
1611:
1607:
1603:
1596:
1593:
1588:
1584:
1579:
1574:
1570:
1566:
1562:
1558:
1554:
1547:
1544:
1539:
1535:
1530:
1525:
1521:
1517:
1516:J. Biol. Chem
1513:
1506:
1503:
1498:
1494:
1490:
1486:
1478:
1475:
1470:
1466:
1461:
1456:
1452:
1448:
1444:
1440:
1436:
1429:
1426:
1421:
1417:
1412:
1407:
1403:
1399:
1396:(5): 963–75.
1395:
1391:
1387:
1380:
1377:
1372:
1368:
1364:
1360:
1356:
1352:
1348:
1344:
1337:
1335:
1331:
1326:
1322:
1318:
1314:
1310:
1306:
1302:
1298:
1291:
1288:
1283:
1279:
1275:
1271:
1267:
1263:
1259:
1255:
1251:
1247:
1240:
1237:
1232:
1228:
1224:
1220:
1215:
1210:
1206:
1202:
1198:
1191:
1188:
1183:
1179:
1174:
1169:
1165:
1161:
1157:
1153:
1149:
1142:
1139:
1134:
1130:
1126:
1122:
1118:
1114:
1107:
1104:
1099:
1095:
1091:
1087:
1083:
1079:
1075:
1071:
1067:
1063:
1055:
1052:
1047:
1043:
1039:
1035:
1031:
1027:
1024:(2): 147–69.
1023:
1019:
1012:
1009:
1004:
1000:
996:
992:
988:
984:
981:(2): 279–90.
980:
976:
968:
965:
960:
956:
951:
946:
941:
936:
932:
928:
924:
920:
916:
909:
906:
901:
897:
893:
889:
885:
881:
878:(2): 263–74.
877:
873:
866:
863:
857:
850:
847:
845:
842:
840:
837:
835:
832:
830:
827:
826:
824:
821:
817:
814:
812:
809:
808:
806:
803:
799:
796:
794:
791:
789:
786:
784:
781:
779:
776:
774:
771:
769:
766:
764:
761:
760:
758:
755:
751:
748:
746:
743:
741:
738:
736:
733:
732:
730:
727:
723:
720:
718:
715:
713:
710:
709:
707:
704:
700:
697:
695:
692:
691:
689:
686:
682:
679:
677:
674:
673:
671:
668:
664:
661:
659:
656:
655:
653:
650:
646:
643:
641:
638:
637:
635:
632:
631:
625:
622:
620:
617:
616:
614:
611:
610:
609:
603:
601:
599:
594:
590:
586:
582:
573:
571:
569:
564:
562:
558:
553:
549:
546:
542:
534:
532:
529:
523:
520:
516:
512:
508:
507:myristoylated
504:
496:
494:
491:
487:
479:
477:
474:
470:
466:
462:
458:
454:
450:
446:
442:
438:
434:
429:
425:
421:
420:transmembrane
417:
409:
407:
405:
401:
397:
393:
389:
385:
381:
377:
373:
369:
368:T lymphocytes
366:receptors on
365:
361:
357:
353:
349:
345:
341:
337:
333:
330:in activated
329:
321:
319:
317:
316:immune system
313:
309:
306:
302:
297:
295:
291:
287:
283:
280:group from a
279:
275:
272:
268:
264:
251:
248:
246:
242:
239:
236:
234:
230:
227:
224:
222:
218:
213:
209:
206:
202:
199:
197:
196:Gene Ontology
193:
190:
187:
184:
181:
178:
174:
171:
168:
166:
162:
159:
156:
154:
150:
147:
144:
142:
138:
135:
134:NiceZyme view
132:
130:
126:
123:
120:
118:
114:
111:
108:
106:
102:
97:
94:
91:
89:
85:
80:
75:
66:
63:
55:
45:
41:
35:
32:This article
30:
21:
20:
4147:Translocases
4144:
4131:
4118:
4105:
4092:
4082:Transferases
4079:
4066:
3923:Binding site
3769:SRC-B family
3738:SRC-A family
3542:
3495:RET receptor
3466:AXL receptor
3388:RYK receptor
3345:DDR receptor
3321:ROR receptor
3297:TIE receptor
3273:LTK receptor
3184:EPH receptor
3151:Trk receptor
3127:HGF receptor
3064:FGF receptor
2871:
2806:
2785:
2591:
2421:eIF-2 kinase
1869:
1789:
1785:
1775:
1748:
1744:
1734:
1699:
1695:
1685:
1658:
1654:
1644:
1609:
1605:
1595:
1560:
1556:
1546:
1519:
1515:
1505:
1488:
1484:
1477:
1442:
1438:
1428:
1393:
1389:
1379:
1349:(1): 65–73.
1346:
1342:
1300:
1296:
1290:
1249:
1245:
1239:
1207:(3): 365–8.
1204:
1200:
1190:
1155:
1151:
1141:
1116:
1112:
1106:
1065:
1061:
1054:
1021:
1017:
1011:
978:
974:
967:
922:
918:
908:
875:
871:
865:
607:
577:
565:
550:
538:
524:
500:
483:
413:
325:
298:
266:
262:
260:
122:BRENDA entry
58:
52:October 2018
49:
33:
3918:Active site
2108:GNA15/GNA16
1894:Calcineurin
1786:Genes Cells
1018:Genes Cells
497:Src and Abl
463:contains a
299:Unlike the
110:IntEnz view
82:Identifiers
4190:Categories
4121:Isomerases
4095:Hydrolases
3962:Regulation
2514:Lim kinase
2465:IÎşB kinase
1986:Transducin
1119:: 259–88.
858:References
583:and tumor
581:metastasis
574:Inhibitors
552:Jak family
503:Src family
480:Regulation
449:Jak family
179:structures
146:KEGG entry
4196:EC 2.7.10
4000:EC number
2872:see also
2778:Apoptosis
2259:Monomeric
1991:Gustducin
1909:G protein
439:) and 3 (
410:Structure
312:apoptosis
278:phosphate
271:cytosolic
99:Databases
4024:Kinetics
3948:Cofactor
3911:Activity
2730:Tyrosine
2675:Arginine
2592:Tyrosine
1816:24871585
1808:10421843
1485:Oncogene
1371:35630246
1046:38301879
1003:32339052
900:13225245
604:Examples
453:integrin
388:cytokine
322:Function
308:2.7.10.2
290:proteins
250:proteins
238:articles
226:articles
183:RCSB PDB
93:2.7.10.2
4180:Biology
4134:Ligases
3904:Enzymes
2925:2.7.10)
2856:EDARADD
2841:Mucin-4
2580:RPS6KA1
2426:EIF2AK3
1882:Calcium
1767:9242667
1726:9111318
1677:7531704
1636:1848670
1587:8756661
1538:7537732
1497:7539119
1469:8164650
1420:7534229
1363:3103925
1325:2420005
1305:Bibcode
1297:Science
1282:4363527
1274:1709258
1254:Bibcode
1231:5591073
1223:8898190
1182:9736615
1173:1170863
1133:9241420
1098:1105841
1090:7845468
1070:Bibcode
1038:9140060
995:8425221
959:7809124
927:Bibcode
892:8293463
825:family
807:family
759:family
731:family
708:family
690:family
672:family
654:family
636:family
615:family
336:B-cells
269:) is a
205:QuickGO
170:profile
153:MetaCyc
38:Please
4166:Portal
4108:Lyases
3842:family
3803:family
3707:family
3678:family
3654:family
3630:family
3606:family
3582:family
3558:family
3497:family
3468:family
3456:AATYK2
3444:family
3409:family
3390:family
3371:family
3347:family
3323:family
3299:family
3275:family
3186:family
3153:family
3129:family
3117:VEGFR3
3112:VEGFR2
3107:VEGFR1
3100:family
3066:family
3053:PDGFRB
3048:PDGFRA
2994:family
2861:PRKCSH
2700:Other
2649:DYRK1B
2644:DYRK1A
2384:Other
2354:Cyclin
2337:Cyclin
1814:
1806:
1765:
1724:
1717:232098
1714:
1675:
1634:
1627:359893
1624:
1585:
1578:231504
1575:
1536:
1495:
1467:
1460:358656
1457:
1418:
1411:398168
1408:
1390:EMBO J
1369:
1361:
1323:
1280:
1272:
1246:Nature
1229:
1221:
1180:
1170:
1152:EMBO J
1131:
1096:
1088:
1062:Nature
1044:
1036:
1001:
993:
957:
947:
898:
890:
416:ligand
354:) and
274:enzyme
233:PubMed
215:Search
201:AmiGO
189:PDBsum
129:ExPASy
117:BRENDA
105:IntEnz
88:EC no.
4060:Types
3854:ZAP70
3520:STYK1
3485:TYRO3
3451:AATYK
3258:EPHB6
3253:EPHB5
3248:EPHB4
3243:EPHB3
3238:EPHB2
3233:EPHB1
3228:EPHA8
3223:EPHA7
3218:EPHA6
3213:EPHA5
3208:EPHA4
3203:EPHA3
3198:EPHA2
3193:EPHA1
3170:NTRK3
3165:NTRK2
3160:NTRK1
3088:FGFR4
3083:FGFR3
3078:FGFR2
3073:FGFR1
3044:PDGFR
3029:CSF1R
3011:INSRR
3001:IGF1R
2982:ERBB4
2977:ERBB3
2972:ERBB2
2819:Other
2757:both:
2664:DYRK4
2659:DYRK3
2654:DYRK2
2616:PTK2B
2601:ZAP70
2568:ROCK2
2563:ROCK1
2524:LIMK2
2519:LIMK1
2507:IRAK4
2502:IRAK3
2497:IRAK2
2492:IRAK1
2480:IKBKG
2458:GSK3B
2453:GSK3A
2448:GSK-3
2363:Lipid
2314:Rhebs
2225:BSCL2
2220:GNG13
2215:GNG12
2210:GNG11
2205:GNG10
2170:GNGT2
2165:GNGT1
2103:GNA14
2098:GNA13
2093:GNA12
2088:GNA11
2063:GNAT3
2058:GNAT2
2053:GNAT1
2048:GNAI3
2043:GNAI2
2038:GNAI1
2033:GNAO1
1812:S2CID
1367:S2CID
1278:S2CID
1227:S2CID
1094:S2CID
1042:S2CID
999:S2CID
950:45528
896:S2CID
816:ZAP70
545:Zap70
384:Zap70
348:IL-2R
165:PRIAM
4152:list
4145:EC7
4139:list
4132:EC6
4126:list
4119:EC5
4113:list
4106:EC4
4100:list
4093:EC3
4087:list
4080:EC2
4074:list
4067:EC1
3760:YES1
3729:TYK2
3724:JAK3
3719:JAK2
3714:JAK1
3695:SRMS
3642:PYK2
3618:MATK
3594:TNK1
3589:ACK1
3565:ABL1
3432:ROS1
3416:MUSK
3378:PTK7
3359:DDR2
3354:DDR1
3335:ROR2
3330:ROR1
3263:EPHX
3034:FLT3
3006:INSR
2967:EGFR
2807:see
2786:see
2687:McsB
2611:PTK2
2551:PAK4
2546:PAK3
2541:PAK2
2536:PAK1
2475:IKK2
2470:CHUK
2443:GSK2
2438:GSK1
2324:RGKs
2319:Raps
2304:Arfs
2299:Rhos
2292:NRAS
2287:KRAS
2282:HRAS
2272:Rabs
2267:ARFs
2200:GNG8
2195:GNG7
2190:GNG5
2185:GNG4
2180:GNG3
2175:GNG2
2152:GNB5
2147:GNB4
2142:GNB3
2137:GNB2
2132:GNB1
2083:GNAQ
2078:GNAL
2073:GNAS
2068:GNAZ
2001:cGMP
1977:cGMP
1957:cAMP
1927:cAMP
1870:see
1804:PMID
1763:PMID
1722:PMID
1673:PMID
1632:PMID
1583:PMID
1534:PMID
1493:PMID
1465:PMID
1416:PMID
1359:PMID
1343:Cell
1321:PMID
1270:PMID
1219:PMID
1201:Cell
1178:PMID
1129:PMID
1086:PMID
1034:PMID
991:PMID
975:Cell
955:PMID
888:PMID
872:Cell
778:YES1
750:TYK2
745:JAK3
740:JAK2
735:JAK1
722:SRMS
681:PYK2
663:MATK
645:TNK1
640:ACK1
619:ABL1
568:SOCS
561:Jak2
557:Tyk2
541:ITAM
362:and
352:EpoR
334:and
267:nRTK
245:NCBI
186:PDBe
141:KEGG
3849:SYK
3840:SYK
3830:TXK
3825:ITK
3820:BTK
3815:BMX
3810:TEC
3801:TEC
3791:LYN
3786:LCK
3781:HCK
3776:BLK
3755:FYN
3750:FGR
3745:SRC
3705:JAK
3690:BRK
3685:FRK
3676:FRK
3666:FER
3661:FES
3652:FES
3637:FAK
3628:FAK
3613:CSK
3604:CSK
3580:ACK
3570:ARG
3556:ABL
3504:RET
3480:MER
3475:AXL
3397:RYK
3311:TEK
3306:TIE
3287:ALK
3282:LTK
3141:RON
3136:MET
3039:KIT
2623:BTK
2309:Ran
2277:Ras
1863:MAP
1794:doi
1753:doi
1749:272
1712:PMC
1704:doi
1663:doi
1659:270
1622:PMC
1614:doi
1573:PMC
1565:doi
1524:doi
1520:270
1455:PMC
1447:doi
1406:PMC
1398:doi
1351:doi
1313:doi
1301:231
1262:doi
1250:351
1209:doi
1168:PMC
1160:doi
1121:doi
1078:doi
1066:373
1026:doi
983:doi
945:PMC
935:doi
880:doi
849:TXK
844:ITK
839:BTK
834:BMX
829:TEC
823:TEC
811:SYK
805:SYK
798:LYN
793:LCK
788:HCK
783:BLK
773:FYN
768:FGR
763:SRC
757:SRC
729:JAK
717:BRK
712:FRK
706:FRK
699:FER
694:FES
688:FES
676:FAK
670:FAK
658:CSK
652:CSK
634:ACK
624:ARG
613:ABL
528:Abl
515:Csk
441:SH3
437:SH2
433:DNA
400:Btk
396:Syk
392:Lyn
376:Lck
372:Src
364:CD8
360:CD4
344:BCR
340:TCR
286:ATP
221:PMC
177:PDB
42:to
4192::
2923:EC
2917::
2741::
1945:Gi
1941:Gs
1810:.
1802:.
1788:.
1784:.
1761:.
1747:.
1743:.
1720:.
1710:.
1700:17
1698:.
1694:.
1671:.
1657:.
1653:.
1630:.
1620:.
1610:11
1608:.
1604:.
1581:.
1571:.
1561:16
1559:.
1555:.
1532:.
1518:.
1514:.
1489:10
1487:.
1463:.
1453:.
1443:14
1441:.
1437:.
1414:.
1404:.
1394:14
1392:.
1388:.
1365:.
1357:.
1347:49
1345:.
1333:^
1319:.
1311:.
1299:.
1276:.
1268:.
1260:.
1248:.
1225:.
1217:.
1205:87
1203:.
1199:.
1176:.
1166:.
1156:17
1154:.
1150:.
1127:.
1117:26
1115:.
1092:.
1084:.
1076:.
1064:.
1040:.
1032:.
1020:.
997:.
989:.
979:72
977:.
953:.
943:.
933:.
923:91
921:.
917:.
894:.
886:.
876:76
874:.
358:.
332:T-
318:.
305:EC
261:A
203:/
4168::
4154:)
4150:(
4141:)
4137:(
4128:)
4124:(
4115:)
4111:(
4102:)
4098:(
4089:)
4085:(
4076:)
4072:(
3896:e
3889:t
3882:v
3055:)
3046:(
2921:(
2907:e
2900:t
2893:v
2732::
2713::
2594::
2414:2
2409:1
2397::
2160:Îł
2158:G
2127:β
2125:G
2028:α
2026:G
1979::
1943:/
1929::
1848:e
1841:t
1834:v
1818:.
1796::
1790:4
1769:.
1755::
1728:.
1706::
1679:.
1665::
1638:.
1616::
1589:.
1567::
1540:.
1526::
1499:.
1471:.
1449::
1422:.
1400::
1373:.
1353::
1327:.
1315::
1307::
1284:.
1264::
1256::
1233:.
1211::
1184:.
1162::
1135:.
1123::
1100:.
1080::
1072::
1048:.
1028::
1022:1
1005:.
985::
961:.
937::
929::
902:.
882::
265:(
65:)
59:(
54:)
50:(
36:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.